Efficacy and safety of inotuzumab ozogamicin and its combination therapies in acute lymphoblastic leukemia: a systematic review and meta-analysis
BackgroundAlthough treatment for acute lymphoblastic leukemia (ALL) has advanced considerably, adults with relapsed or refractory (R/R) disease continue to face a grave prognosis. Inotuzumab ozogamicin (InO), a CD22-directed antibody–drug conjugate, represents a promising development for B-cell ALL....
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2025-11-01
|
| Collection: | Frontiers in Oncology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1613777/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|